** Shares of cancer drug developer iTeos Therapeutics ITOS.O rise 4.5% to $7.15 in the afternoon trade
** Company reports Q4 net loss of $1.01 per share, compared to analysts' estimates of a loss of $1.06 per share, according to data compiled by LSEG
** ITOS expects its cash balance of $655 million to provide a runway through 2027
** ITOS down 38.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。